RWD Study in HER2+ mBC Patients in Third-Line Therapy

Official Title

Real-World Data Study in HER2+ Metastatic Breast Cancer Patients in Third-Line Therapy


This retrospective observational study will collect Canadian real-world data (RWD) from HER2+ metastatic breast cancer (mBC) patients to describe treatment sequences of all therapies received in the metastatic setting, to measure overall survival (OS), progression free survival (PFS), time to next active anti-cancer therapy, and to estimate the health resources utilization (HRU) during third-line therapy.

Trial Description

Primary Outcome:

  • To describe treatment sequences of all lines of therapy received by HER2 + mBC patients in Canada
  • To describe the brain metastatic HER2+ mBC subpopulation during third line
  • To describe radiation therapies received for brain metastasis in HER2+ mBC during third line.
  • To calculate the median overall survival (OS) of HER2+ mBC patients who received third-line therapy in Canada.
  • To calculate the median PFS of HER2+ mBC patients receiving third-line therapy in Canada
  • To calculate the median time to next active anticancer treatment of HER2+ mBC patients receiving third-line therapy in Canada
  • To assess HRU for HER2+ mBC patients in Canada during third-line therapy.
The proportion of treatment received during all lines of therapy in the metastatic setting will be described. The 2-year survival rate and median OS with interquartile range (IQR) for third-line therapy will be calculated. HRU data and costs during third-line therapy will be collected.

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society